Actinogen Medical Limited chart

Last update: 2021-02-19
Key statistics and financials
Revenue per share 0.00
Dividend & YieldN/A$ (N/A)
Beta 2.73
Market capitalization 149.06M
Operating cash flow -6.39M
ESG Scores unknown

Company description

Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological diseases in Australia. The company is developing Xanamem, a therapy for Alzheimer's disease, and cognitive impairment associated with schizophrenia, diabetes, and other disorders; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, and placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild Alzheimer's disease. It is also developing XanaHES, a single blinded, central reader blinded, placebo-controlled, and dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is headquartered in Sydney, Australia.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2019-06-30 2020-06-30 2021-06-30 2022-06-30
Change To Liabilities -215.65k 75.7k 110.3k 688.81k
Total Cashflows From Investing Activities 71.77k -22.76k -6.19k -2.94k
Net Borrowings -77.74k -77.74k -84.1k -71.17k
Total Cash From Financing Activities 8.17M 282.26k 10.11M 12.42M
Change To Operating Activities 4.79k 24.7k -84.22k 28.52k
Issuance Of Stock 8.48M 360k 10.91M 13.32M
Net Income -9.89M -5.33M -3.92M -9.5M
Change In Cash -2.26M -2.6M 8.38M 2.95M
Effect Of Exchange Rate 13.39k 13.39k 13.39k 13.39k
Total Cash From Operating Activities -10.5M -2.86M -1.72M -9.52M
Depreciation 353.5k 412.93k 386.69k 400.67k
Change To Account Receivables -1.36M 1.77M 1.49M -2.41M
Other Cashflows From Financing Activities -317.25k -715.87k -715.87k -831.29k
Change To Netincome 604.85k 194.49k 289.28k 1.27M
Capital Expenditures -22.76k -22.76k -6.19k -2.94k

Income Statement 2019-06-30 2020-06-30 2021-06-30 2022-06-30
Research Development 10.9M 5.54M 2.41M 8.21M
Income Before Tax -9.89M -5.33M -3.92M -9.5M
Net Income -9.89M -5.33M -3.92M -9.5M
Selling General Administrative 3.09M 2.77M 2.82M 3.27M
Gross Profit 4.86M 3.52M 1.98M 3.64M
Ebit -9.61M -5.4M -3.92M -9.53M
Operating Income -9.61M -5.4M -3.92M -9.53M
Interest Expense -7.99k -28.88k -22.32k -18.48k
Income Tax Expense
Total Revenue 4.86M 3.52M 1.98M 3.64M
Cost Of Revenue
Total Other Income ExpenseNet -280.34k 65.17k 4.77k 35.99k
Net Income From Continuing Ops -9.89M -5.33M -3.92M -9.5M
Net Income Applicable To Common Shares -9.89M -5.33M -3.92M -9.5M

Balance Sheet Statement 2019-06-30 2020-06-30 2021-06-30 2022-06-30
Total Liabilities 557.39k 1.05M 920.32k 1.57M
Total Stockholder Equity 15.66M 10.89M 17.46M 21.74M
Other Current Liabilities 183.11k 400.85k
Total Assets 16.22M 11.94M 18.38M 23.31M
Common Stock 51.44M 51.32M 64.16M 81.88M
Other Current Assets 400.85k
Retained Earnings -39.2M -44.53M -48.44M -57.94M
Treasury Stock 3.42M 4.1M 1.74M -2.2M
Cash 7.64M 5.04M 13.46M 16.37M
Total Current Liabilities 557.39k 743.82k 755.05k 1.48M
Other Stockholder Equity 3.42M 4.1M 1.74M -2.2M
Property, Plant, and Equipment 391.04k 253.96k 168.97k
Total Current Assets 12.53M 8.16M 15.09M 20.42M
Net Tangible Assets 12M 7.54M 14.42M 19.02M
Net Receivables 4.83M 2.66M 1.54M 3.94M
Accounts Payable 282.82k 46.84k 392.19k 898.74k


Insider Transactions

Here are the insider transactions of stock shares related to Actinogen Medical Limited:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Brooke (Geoffrey E)Purchase at price 0.05 per share.D2022-05-20Non Executive Chairman340k
Gourlay (Steve Ph.D.)Purchase at price 0.04 per share.D2022-05-12Chief Executive Officer2M
Gourlay (Steve Ph.D.)Other at price 0.10 per share.D2022-04-06Chief Executive Officer797.22k
Brooke (Geoffrey E)Other at price 0.09 per share.D2021-12-20Non Executive Chairman222.22k
McCormas (Malcolm)Other at price 0.09 per share.D2021-12-20Director (Non-Executive)222.22k
Morstyn (George)Other at price 0.09 per share.D2021-12-20Director (Non-Executive)777.78k
Brooke (Geoffrey E)Other at price 0.15 per share.D2021-11-18Non Executive Chairman2.5M
McCormas (Malcolm)Other at price 0.15 per share.D2021-11-18Director (Non-Executive)1M
Morstyn (George)Other at price 0.15 per share.D2021-11-18Director (Non-Executive)1M
Morstyn (George)Purchase at price 0.02 per share.D2021-03-24Director (Non-Executive)2.55M
Ketelbey (John William)D2021-02-08Former11.17M
Brooke (Geoffrey E)Acquisition at price 0.02 per share.D2020-11-17Non Executive Chairman265k
Ketelbey (John William)Acquisition at price 0.02 per share.D2020-11-17Chief Executive Officer128.58k
Ketelbey (John William)Acquisition at price 0.02 per share.D2020-11-17Chief Executive Officer62.18k
Ketelbey (John William)Acquisition at price 0.02 per share.D2020-11-17Chief Executive Officer1.8M
McCormas (Malcolm)Acquisition at price 0.02 per share.D2020-11-17Director (Non-Executive)100k
Morstyn (George)Acquisition at price 0.02 per share.D2020-11-17Director (Non-Executive)40k
Ketelbey (John William)D2020-01-31Chief Executive Officer3M
Loveridge (Jason)D2018-11-28Retired21.88M
Brooke (Geoffrey E)Other at price 0.04 per share.D2018-07-13Non Executive Chairman300k
Ketelbey (John William)Other at price 0.04 per share.D2018-07-13Chief Executive Officer600k
Morstyn (George)Purchase at price 0.04 per share.D2018-06-01Director (Non-Executive)200k
Brooke (Geoffrey E)Other at price 0.03 per share.D2018-01-22Non Executive Chairman625k
Uvarov (Anton)D2017-08-14Former187.24k
Brooke (Geoffrey E)Purchase at price 0.05 per share.D2017-03-29Non Executive Chairman400k
Rogers (Martin Frederick)D2016-11-30Retired11.41M
Ketelbey (John William)Purchase at price 0.04 per share.D2015-12-24Chief Executive Officer10.91k
Ketelbey (John William)Other at price 0.07 per share.D2015-05-20Chief Executive Officer157.89k
Loveridge (Jason)Other at price 0.07 per share.D2015-05-20Director (Non-Executive)157.89k
Rogers (Martin Frederick)Other at price 0.07 per share.D2015-05-20Non Executive Chairman157.89k
Uvarov (Anton)Other at price 0.07 per share.D2015-05-20Director (Non-Executive)157.89k
De Kauwe (Brendan)Other at price 0.02 per share.D2014-12-01Director (Non-Executive)2.5M
Uvarov (Anton)Other at price 0.02 per share.D2014-12-01Director (Non-Executive)2M
Zohar (David Alan)D2013-12-16Former17.44M
De Kauwe (Brendan)Other at price 0.01 per share.D2013-12-12Director (Executive)2M
Parasiliti (Daniel)Other at price 0.01 per share.D2013-12-12Director (Non-Executive)1M
England (Simon Christopher)D2013-09-23Former500k
Pervan (Zhukov)D2013-09-23Former17.2M
Pervan (Zhukov)Purchase at price 0.02 per share.D2013-07-09Chairman of the Board66.67k
Zahar (Shoshanna)D2013-06-30Secretary100k
Zohar (David Alan)Purchase at price 0.02 per share.D2013-06-19Director (Executive)221.83k
Zohar (David Alan)Purchase at price 0.02 per share.D2013-04-08Director (Executive)142.02k
Zohar (David Alan)Purchase at price 0.02 per share.D2013-04-02Director (Executive)20k
Zohar (David Alan)Purchase at price 0.03 per share.D2012-05-25Director (Executive)30k
Zohar (David Alan)Sale at price 0.05 per share.D2011-12-13Director (Executive)200k
Zohar (David Alan)D2011-10-17Director (Executive)10M
Keast (David)D2011-10-17Director (Executive)10M
Pervan (Zhukov)D2011-10-17Chairman of the Board10M
Zohar (David Alan)Purchase at price 0.08 per share.D2010-10-13Director (Executive)20k
Zohar (David Alan)Purchase at price 0.08 per share.D2010-09-21Director (Executive)4.97k
Zohar (David Alan)Purchase at price 0.10 per share.D2010-08-06Director (Executive)60k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Actinogen Medical Limited. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Actinogen Medical Limited

Here is the result of two systematic investment strategies applied to Actinogen Medical Limited. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Actinogen Medical Limited

The following chart shows the equity curve of the two systematic investment strategies applied to Actinogen Medical Limited:

Actinogen Medical Limited automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -36.27% on the backtest period.

Performance at glance

Performance

-36.27 %

Latent gain

-816.04 $

Invested capital

2249.98 $

Annualized return

-8.64 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Actinogen Medical Limited

This is the result of two momentum investment strategies applied to Actinogen Medical Limited. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Actinogen Medical Limited

The following chart shows all the entries opened by the momentum investment system on Actinogen Medical Limited:

Actinogen Medical Limited momentum entries
  • The first momentum investment strategy would give -11.09% of return on Actinogen Medical Limited. That represents -582.42$ of latent gain with 5250.07$ of employed capital.
  • The second momentum investment strategy would give -18.64% of return on Actinogen Medical Limited. That represents -419.44$ of latent gain with 2249.99$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-11.09 %

Latent gain

-582.42 $

Invested capital

5250.07 $

Annualized return

-18.18 %
Performance at glance (2Q Momentum)

Performance

-18.64 %

Latent gain

-419.44 $

Invested capital

2249.99 $

Annualized return

-5.01 %

Momentum equity curve on Actinogen Medical Limited

The following chart shows the equity curve of the two momentum strategies applied to Actinogen Medical Limited:

Actinogen Medical Limited momentum equity

Note: the dividends potentially given by Actinogen Medical Limited are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Actinogen Medical Limited

The following chart shows the employed capital evolution of the two momentum strategies on Actinogen Medical Limited since the beginning:

Actinogen Medical Limited

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Actinogen Medical Limited

Buy the dip entry openings on Actinogen Medical Limited

Actinogen Medical Limited

The performance achieved by the robo-advisor on Actinogen Medical Limited is -40.0%. That represents -100.0$ of latent gain with 250.01$ of employed capital. The following chart shows Actinogen Medical Limited stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Actinogen Medical Limited, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-40.0 %

Latent gain

-100.0 $

Invested capital

250.01 $

Annualized return

-18.18 %

Equity curve of the strategy applied to Actinogen Medical Limited

The following chart shows the result of the investment strategy applied to Actinogen Medical Limited:

Actinogen Medical Limited

Note: the dividends potentially given by Actinogen Medical Limited are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Actinogen Medical Limited

The following chart shows the employed capital evolution since the beginning of the investment strategy on Actinogen Medical Limited:

Actinogen Medical Limited

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Actinogen Medical Limited

In this section, I will compare the three previous investment strategies applied to Actinogen Medical Limited.

Equity curve comparison on Actinogen Medical Limited

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Actinogen Medical Limited investment strategy comparison

Employed capital comparison on Actinogen Medical Limited

Actinogen Medical Limited investment comparison

Performance comparison on Actinogen Medical Limited

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -36.27% -816.04$ 2249.98$ -8.64%
Momentum 1 quarter -11.09% -582.42$ 5250.07$ -2.8%
Momentum 2 quarters -18.64% -419.44$ 2249.99$ -5.01%
Non-directional -40.0% -100.0$ 250.01$ -18.18%
Annualized return comparison

Automatic investment

-8.64 %

Momentum 1Q

-5.01 %

Momentum 2Q

-5.01 %

Non-directional

-18.18 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Actinogen Medical Limited:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Actinogen Medical Limited and the other stocks. There may be false positives or some missing correlated stocks. If the price of Actinogen Medical Limited does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Actinogen Medical Limited
Country Australia
City Sydney
Address 109 Pitt Street
Phone 61 2 8964 7401
Website www.actinogen.com.au
FullTime employees
Industry Biotechnology
Sector Healthcare
Exchange XASX
Ticker ACW.XASX
Market www2.asx.com.au

Actinogen Medical Limited ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown